AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00521937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermagen®
Description: Weekly topical applications
Study NCT04588480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: BNT162b2 (intramuscular injection)
Study NCT04588480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (intramuscular injection)
Study NCT03553875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
Study NCT03553875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
Study NCT02593396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride sustained-release
Description: Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
Study NCT02593396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
Study NCT03399578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
Study NCT03495284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato-based side dish
Description: Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks
Study NCT03495284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Refined grain-based
Description: Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
Study NCT01450124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boswellic acids (BOSWELAN)
Description: 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
Study NCT02919176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Mirabegron 50 mg/day
Study NCT02919176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg/day
Study NCT02919176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron and Pioglitazone
Description: Mirabegron 50 mg/day and Pioglitazone 30 mg/day
Study NCT03970590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTC Intervention
Description: An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran\] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months
Study NCT03970590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 6-month HTN management assessment text messages without narrative component
Study NCT02886793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose
Study NCT00853827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00853827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300 mg
Study NCT03691428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wish Outcome Obstacle Plan
Description: 1. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan.
Study NCT03691428 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wish Outcome Obstacle Plan
Description: 1. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan.
Study NCT04072822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra and Zinc
Description: Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
Study NCT04072822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
Study NCT04072822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Matching placebo
Study NCT03014596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assert
Description: The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
Study NCT04420195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Tacrolimus
Description: Envarsus XR is an FDA-approved drug for the prophylaxis of organ rejection in de novo kidney transplant patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants. Envarsus XR is a novel extended-release formulation of tacrolimus created using MeltDose technology. Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.
Study NCT04420195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-Release Tacrolimus
Description: Historical cohort of 20 subjects who will be maintained on IR tacrolimus following transplant. Dosing will be converted on an individual basis (Capsules: 0.5 mg, 1 mg and 5 mg or Injection: 5 mg) . All patients will be initiated on IR tacrolimus either under the tongue (sublingual) or as a solution given through a tube placed through the nose into the stomach, which is standard of care for all lung transplant recipients.
Study NCT01191463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mung Bean Meal
Description: 50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
Study NCT01191463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mung Bean Meal
Description: 50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
Study NCT01191463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guava
Description: A fresh Guava fruit will be provided raw (approx 100g fresh weight)
Study NCT05399394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
Study NCT05399394 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.
Study NCT01122420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-Setting Tool
Description: Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
Study NCT01122420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Web Sites
Description: Access to publicly available health-related web sites
Study NCT00432029 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Forearm blood flow measurement, Flow mediated dilation (FMD)
Description: Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
Study NCT00432029 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light
Description: Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
Study NCT04897737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIVST and enhanced adherence biofeedback
Description: The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use.
Study NCT04897737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Orasure/UrSure test
Description: See above
Study NCT00478335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: 25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
Study NCT00478335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitonin
Description: one nasal spray daily for 4 days
Study NCT00478335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide/amiloride
Description: 25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
Study NCT00478335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrochlorothiazide/amiloride
Description: 25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
Study NCT00478335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: 50 mg QD or 50 mg BID x 8 days depending on subject weight
Study NCT00478335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: indomethacin
Description: 50 mg QD or 50 mg BID x 8 days depending on subject weight
Study NCT00478335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for sildenafil
Description: one tablet daily for 4 days
Study NCT00478335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for calcitonin
Description: one nasal spray daily
Study NCT02667535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate
Description: Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days.
Study NCT03869918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Exercise at home or through a class as chosen by the subject.
Study NCT03109704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine upper thoracic spine thrust manipulation
Description: The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
Study NCT03109704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Seated upper thoracic spine thrust manipulation
Description: The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
Study NCT03109704 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust.
Study NCT03058991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance Intervention
Description: See arm/group description.
Study NCT03058991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Intervention
Description: See arm/group description.
Study NCT02406417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigation for pituitary dysfunction by blood tests.
Description: Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
Study NCT03058991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Informational Intervention
Description: See arm/group description.
Study NCT01345604 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transcruciate injection of 20cc of normal saline
Description: Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
Study NCT02406417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic function tests and pituitary imaging
Description: Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
Study NCT01345604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcruciate injection of 20 cc of 0.5% Ropivacaine
Description: Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
Study NCT00234858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Hyzaar) losartan/hydrochlorothiazide
Description: 50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
Study NCT02881749 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total skin electron beam therapy (TSEBT)
Description: TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy.
Study NCT02362308 — intervention group
Intervention type: OTHER
Intervention: Adrenalectomy
Description: Adrenalectomy for treatment of primary aldosteronism, according to standard of care
Study NCT01333436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Meal
Description: During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
Study NCT01204957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed and Soy Protein
Description: 5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
Study NCT01204957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo and Soy Protein
Description: 5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
Study NCT01296165 — intervention group
Intervention type: BEHAVIORAL
Intervention: Analysing the behaviours of travellers while visiting India
Description: For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value \<0.05 will be deemed to represent statistical significance.
Study NCT02257320 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TMJ NextGeneration(TM)
Description: The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
Study NCT02740270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWN323
Study NCT02740270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Study NCT03829839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo nasalspray
Description: The placebo nasalspray contain identical ingredients except for the active agent itself.
Study NCT03829839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo pill contain identical ingredients except for the active agent itself.
Study NCT03403088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: • Group LA
Description: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity